Andreas and Thomas Strüngmann (via Agreus Group)
December 10, 2021 07:14 AM ESTUpdated 11:34 AM
Deals
Bioregnum

Bil­lion­aire BioN­Tech back­ers have been kick­ing the tires at No­var­tis' big gener­ics arm — re­port

While the ul­ti­mate fate of No­var­tis’ big gener­ics arm San­doz may still be up in the air, there’s no doubt it’s in play as a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times